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Abstract  Targeted  therapies  have  considerably  improved  the  prognosis  of  patients  with
metastatic  renal  cancer  (mRCC)  but  there  are  no  reliable  response  assessment  criteria  reﬂecting
the clinical  beneﬁts,  because  there  is  no  regression  in  size,  or  it  is  delayed.  Such  criteria  would
help early  identiﬁcation  of  non-responders,  who  would  then  beneﬁt  from  a  change  of  treatment,
and would  avoid  their  being  subjected  to  unnecessary  side  effects  related  to  the  treatment.  We
will review  the  imaging  techniques  currently  available  for  evaluating  tumour  response  in  mRCC
patients,  including  the  response  evaluation  criteria  in  solid  tumours  (RECIST),  the  Choi  criteria,
the modiﬁed  Choi  criteria,  and  the  CT  size  and  attenuation  criteria  (SACT).  We  will  also  dis-
cuss functional  imaging  techniques,  which  are  based  on  the  physiological  characteristics  of  the
tumours, such  as  perfusion  CT,  magnetic  resonance  imaging  or  ultrasound  (DCE-CT,  DCE-MRI,
DCE-US),  diffusion  MRI,  BOLD  MRI  and  new  positron  emission  tomography  (PET)  tracers.  It  is
not possible  at  present  to  propose  a  unanimously  acknowledged  criterion  for  evaluating  tumour
response  to  targeted  therapy.  However,  there  is  a  real  need  for  this  according  to  oncologists  and
the pharmaceutical  industry,  and  radiologists  need  to  be  involved  in  reﬂecting  on  the  subject.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.∗ Corresponding author. Radiology Department, Hôpital Européen Ge
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Renal  tumours  represent  2%  of  all  malignant  tumours  in
dults,  and  are  the  13th  most  common  cancer  worldwide,
ith  208,000  new  cases  and  102,000  deaths  per  year  [1].
he  incidence  of  renal  cancer  and  its  mortality  rate  have
een  constantly  rising  throughout  the  world  by  2—3%  per
ecade  [2,3].
The  large  majority  of  kidney  cancers  are  renal  cell  carci-
omas  (RCC),  histologically  classiﬁed  as  clear  cell  (60—80%),
apillary  (10—15%)  and  chromophobic  (5—10%)  cancers.
hen  the  condition  remains  localised,  RCC  can  be  treated
y  surgery  and  thus  be  cured.  In  contrast,  in  the  20—30%  of
etastatic  (mRCC)  patients,  either  synchronously  or  some
ime  after  the  surgery,  the  prognosis  was  until  recently  poor,
ith  median  overall  survival  of  8  to  10  months  and  a survival
ate  at  5  years  of  less  than  10%  [2].
This  poor  prognosis  was  explained  by  the  limited
herapeutic  options  for  patients  with  metastatic  renal  can-
er,  since  mRCC  is  resistant  to  conventional  cytotoxic
hemotherapy  [4].  mRCC  patients  were  usually  treated
ith  immunotherapy,  as  certain  RCC  tumours  are  capa-
le  of  provoking  an  immune  response.  The  anti-tumour
ffects  most  consistently  observed  were  with  interferon  
nd/or  interleukin-2.  A  few  patients  could  thus  obtain  long-
erm  complete  remission.  Interferon  ,  the  most  frequently
dministered  cytokine,  led  to  an  objective  response  of  7.5%
nd  median  overall  survival  (OS)  of  13  months  [4].During  the  last  7  to  8  years,  the  introduction  of  therapies
argeted  against  tumour  vessels  (anti-angiogenics),  includ-
ng  VEGF  and  mTOR  inhibitors,  has  radically  changed  the
herapeutic  arsenal  for  mRCC  and  considerably  improved
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Table  1  Targeted  therapies  for  renal  cancer  with  the  actual  a
Drug  Target  Method  o
administr
Monoclonal  treatments
Bevacizumab  (Avastin®)  VEGF  (Vascular
Endothelial
Growth  Factor)
Intraveno
Bevacizumab  VEGF  Intraveno
Tyrosine  kinase  inhibitors  (TKI)
Sunitinib  (Sutent®)  VEGFR  1.2.3  and
PDGFR  and  c-Kit;
FLT3;  RET
Oral  
Sorafenib  (NEXAVAR®)  VEGFR  1.2.3  and
PDGFR  and  c-Kit;
FLT3;  RET;  RAF
Oral  
Pazopanib  (Votrient®)  VEGFR  1.2.3  and
PDGFR  and  c-Kit
Oral  
mTOR  inhibitors
Temsirolimus  (Torisel®)  mTOR  Intraveno
Everolimus  (Aﬁnitor®)  mTOR  Oral  S.  Ammari  et  al.
he  prospects  for  patients  with  this  disease.  In  Decem-
er  2005,  the  Food  and  Drug  Administration  approved
he  ﬁrst  targeted  agent,  sorafenib,  for  treating  patients
ith  cytokine-refractory  mRCC.  Following  this,  ﬁve  other
argeted  agents  have  been  approved  for  treating  mRCC,
ncluding  sunitinib,  temsirolimus,  everolimus,  bevacizumab
n  combination  with  interferon  , and  more  recently,
azopanib.  These  products  have  now  replaced  immunother-
py  in  the  majority  of  patients  with  mRCC  (Table  1)  and
roduce  signiﬁcantly  better  progression-free  survival  in
hese  patients  [4], with  median  overall  survival,  depending
n  the  studies,  seeming  to  reach  2  to  3  years  if  all  the  thera-
eutic  options  that  we  have  at  present  are  added  together.
In  parallel  with  the  progress  in  the  therapeutic  area,
esearch  has  been  conducted  to  accurately  assess  the
herapeutic  response  to  these  new  agents.  Response  to  ther-
peutic  drugs  is  usually  assessed  by  evaluating  the  response
f  solid  tumours  using  the  Response  Evaluation  Criteria  In
olid  Tumours  [5],  or  RECIST,  which,  since  their  introduc-
ion  in  2000,  have  gradually  become  the  standard  method
or  evaluating  treatments  for  solid  (non-haematological)
umours.  The  RECIST  response  depends  on  change  in  the
um  of  the  single  dimension  measurements  of  target  tumour
esions  for  a given  imaging  procedure.
Although  RECIST  are  clinically  relevant  for  conventional
hemotherapy,  this  does  not  seem  to  be  the  case  for  the  new
eneration  of  anti-cancer  agents,  because  targeted  agents
requently  induce  stabilisation  of  the  disease  rather  than
egression  [6,7]  and  lead  to  tumour  necrosis  [8—10].  These
argeted  agents  produce  a net  clinical  beneﬁt  but  a  low
gents  (molecular  targets  and  method  of  administration).
f
ation
Progression-free
survival  (PFS  in
months)
Overall
survival  (OS
in  months)
Reference
us  10.2  23.3  Escudier
et  al.,  2007,
2010  [6,74]
us  8.5  18.3  Rini  et  al.,
2008,  2010
[75,76]
11  26  Motzer  et  al.,
2007,  2009
[11,22]
5.5  17.8  Escudier
et  al.,  2007,
2009  [48,77]
9.2  Not
available
Stermberg
et  al.,  2010
[78]
us  5.5  10.9  Hudes  et  al.,
2007  [7]
4.9  14.8  Motzer  et  al.,
2010,  2008
[79,80]
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response  rate  according  to  RECIST  in  the  treatment  of  renal
cancer,  whether  the  agent  used  is  sunitinib  [11],  sorafenib
[12]  or  bevacizumab  +  interferon  [12].  Increase  in  the  size  of
the  tumour  has  also  been  described  associated  with  necrosis,
mimicking  disease  progression.  Several  teams  have  conse-
quently  developed  new  criteria  based  on  size,  on  changes  in
attenuation  (density)  in  computed  tomography  (CT)  [10,13],
in  perfusion  CT  (DCE-CT)  [14],  magnetic  resonance  imag-
ing  (DCE-MRI)  [15]  or  ultrasound  (DCE-US)  [16,17],  or  new
tracers  in  positron  emission  tomography  (PET)  [18].  With
these  criteria,  non-responders  could  be  identiﬁed  early;
they  would  then  beneﬁt  from  a  rapid  change  in  therapy,
which  would  avoid  their  continuing  with  costly  but  ineffec-
tive  treatment  causing  side  effects.
In  this  update,  we  will  review  the  imaging  techniques
currently  available  and  the  criteria  proposed  for  evaluating
tumour  response  in  patients  with  mRCC.
Methods of evaluating the efﬁcacy of new
targeted therapies
For  CT,  various  criteria  will  be  discussed,  including  RECIST,
modiﬁed  RECIST,  the  Choi  criteria,  the  modiﬁed  Choi  crite-
ria,  and  the  Size  and  Attenuation  in  CT  (SACT)  criteria.
The  use  of  functional  imaging  techniques  will  also  be  dis-
cussed,  such  as  perfusion  CT,  MRI  or  ultrasound  (dynamic
contrast-enhanced  acquisition  or,  respectively,  DCE-CT,  DCE-
MRI,  DCE-US),  diffusion  or  BOLD  MRI,  and  PET.
Criteria based on size
RECIST  1.0
The  reference  treatment  evaluation  method  is  based  on
measurement  of  the  size  of  the  lesions.  In  2000,  in  order
to  simplify  and  standardise  clinical  trial  assessment  crite-
ria,  the  European,  American  and  Canadian  cancer  research
organisations  set  out  the  Response  Evaluation  Criteria  In
Solid  Tumours  (RECIST)  [5].  These  criteria  only  apply  to  solid
tumours  and  are  based  on  measuring  the  longest  diameter
of  a  patient’s  tumour  lesions.
The  principle  is  to  make  an  exhaustive  list  of  the  lesions,
whether  they  are  primary  or  secondary,  before  beginning
the  treatment.  They  will  then  be  monitored  in  later  exam-
inations  to  determine  whether  they  are  responding  to
treatment  or  not.
Two  types  of  lesion  are  deﬁned  in  the  initial  examination:
• target  lesions  (Fig.  1):  deﬁned  as  lesions  where  the  longest
diameter  is  greater  or  equal  to  10  mm  and  where  the  bor-
ders  are  sufﬁciently  well  deﬁned  for  their  measurement
to  be  considered  as  reliable.  The  total  sum  of  the  great-
est  diameters  (SGD)  of  all  the  target  lesions  selected  is
calculated  and  serves  as  a  reference.  A  maximum  of  10
lesions  are  selected  per  patient,  and  ﬁve  per  organ;
• non-target  lesions  (Fig.  2):  deﬁned  as  the  exhaustive  list
of  all  remaining  lesions,  not  selected  as  targets  because
they  were  too  small  (<  10  mm)  or  because  their  measure-
ment  was  considered  to  be  unreliable  since  their  borders
were  difﬁcult  to  deﬁne  (bone  lesions,  leptomeningeal
lesions,  ascites,  pleural  effusion  or  pericarditis,  carci-
nomatous  lymphangitis,  etc.),  plus  measurable  lesions
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greater  than  10  mm  which  were  not  selected  as  targets
because  there  were  more  than  ﬁve  of  them  per  organ,  or
they  totalled  more  than  10.
During  patient  follow-up  examinations,  response  to  treat-
ent  is  determined  by  changes  in  each  category  of  lesions
s  follows:
target  lesion  response  (Fig.  1)  is  evaluated  from  the
percentage  modiﬁcation  of  the  sum  of  their  greatest
diameters:
◦ CR  (complete  response):  disappearance  of  all  the  target
lesions,
◦ PR  (partial  response):  reduction  greater  or  equal  to  30%
relative  to  the  pretreatment  sum,
◦ PD  (progressive  disease):  increase  greater  or  equal
to  20%  relative  to  the  smallest  sum  measured  during
follow-up,
◦ SD  (stable  disease):  neither  CR,  nor  PR,  nor  PD  (%
change  relative  to  the  smallest  sum  measured  during
follow-up);
the  response  of  the  non-target  lesions  is  assessed  subjec-
tively  by  the  observer:
◦ CR:  complete  disappearance  of  all  the  non-target
lesions  and  normalisation  of  tumour  markers,
◦ PD:  ‘unequivocal  progression’  of  non-target  lesions
(left  to  the  observer’s  judgement),
◦ SD:  neither  CR,  nor  PD,  i.e.  the  persistence  of  one
or  more  non-target  lesions  and/or  concentrations  of
tumour  markers  above  normal;
the  appearance  of  a new  lesion  or  lesions:
◦ no:  no  new  lesion,
◦ yes:  appearance  of  a  new  lesion  or  lesions;
the  overall  response  is  a  combination  of  the  preceding
answers:  complete  response,  partial  response,  stable  dis-
ease  or  progressive  disease  (Table  2).
ECIST  1.1
he  RECIST  were  updated  at  the  beginning  of  2009  [19]
ased  on  an  analysis  of  the  literature  and  simulations  from  a
atabase  including  more  than  6500  patients  and  more  than
8,000  lesions.  The  new  version  is  known  as  version  1.1  (the
ormer  becoming  1.0)  (Table  3).
The  main  modiﬁcations  are  as  follows:
the  maximum  number  of  target  lesions  selected  changed
from  10  to  ﬁve  per  patient  and  from  ﬁve  to  two  per  organ;
the  particular  features  of  lymph  nodes  were  taken  into
account  and  their  shortest  axis  must  be  measured  (not
the  longest  axis  as  for  other  lesions).  A  lymph  node  may
be  chosen  as  a  target  lesion  if  its  small  axis  measures
greater  or  equal  to  15  mm,  and  as  a  non-target  lesion  if
its  short  axis  is  greater  or  equal  to  10  mm  and  less  than
15  mm.  With  a  short  axis  less  than  10  mm,  it  is  normal.
Thus,  the  sum  of  the  greatest  diameters  in  a  patient  with
a  complete  response  may  not  be  zero,  if  certain  of  his
targets  were  lymph  nodes  and  they  each  measured  less
than  10  mm;
target  lesions  will  have  progressed  if  the  sum  of  the  great-
est  diameters  has  increased  by  greater  or  equal  to  20%
relative  to  the  reference  sum,  and  if  this  increase  is
greater  or  equal  to  5  mm  in  absolute  terms;
several  examples  are  given  to  clarify  ‘unequivocal
progression’  of  non-target  lesions.  In  particular,  the
530  S.  Ammari  et  al.
Figure 1. RECIST target lesions before and after treatment. Three lesions can be considered as measurable and were therefore chosen
as target lesions in this patient. a: 30 mm lung lesion; b: left external iliac adenomegaly measuring 21 mm in the short axis; c: peritoneal
carcinomatosis of the greater omentum measuring 65 mm  in contact with the greater curvature of the stomach. The sum of the greatest
pretreatment diameters for this patient was assessed as 30 + 21 + 65 = 116 mm. After treatment, all lesions had decreased in size (respectively
d, e, f). The post-treatment sum of the greatest diameters for this patient was assessed as 16 + 10 + 39 = 65 mm. There is a 44% reduction in
the target lesions, which constitutes a partial response. Image d also shows a decrease in the other pulmonary lesions, deﬁned as non-target
lesions.
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Figure 2. Non-target lesions according to RECIST. a: poorly limited contrast uptake of the left paravertebral muscle; b, c: lung lesions of
less than 10 mm with ground-glass appearance. These lesions cannot be reliably measured and their evolution must be assessed qualitatively
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progression  of  a  single  lesion  is  insufﬁcient  to  declare
progression;
• the  presence  of  new  lesions  must  be  unequivocal  to
declare  the  patient  as  progressing.  This  new  version  offers
a  guide  for  using  PET  to  determine  the  metastatic  nature,
or  otherwise,  of  new  lesions.
Modiﬁed  RECIST
Many  studies  have  applied  RECIST  to  evaluate  response  to
targeted  therapies  in  mRCC  [20—22].  However,  achieving  an
objective  response  (a  30%  decrease  in  the  sum  of  the  size
of  target  lesions)  can  take  several  months  [11,22].  Indeed,
the  expected  effect  of  targeted  agents  in  mRCC  is  stability
rather  than  signiﬁcant  tumour  regression.  Consequently,
using  statistical  analysis,  Thiam  et  al.  [23]  sought  to
determine  a  threshold  for  evaluating  size  that  would  best
i
w
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Table  2 Evaluation  of  overall  response  according  to  the  RECIS
Lesion  category  Responses
Target  lesions  CR  CR  PR  
Non-target  lesions  CR  SD  No  PD  
New  lesions  No  No  No  
Overall  response  CR  PR  PR  
CR: complete response; PR: partial response; SD: stable disease; PD: peﬂect  beneﬁt  from  treatment  in  terms  of  progression-free
urvival  (PFS)  (Table  3).
Taking  PFS  as  the  criterion  of  clinical  beneﬁt,  thresh-
lds  of  variation  in  the  sum  of  the  greatest  diameters  from
45%  to  +10%  were  tested  on  334  patients  treated  with  suni-
inib  for  mRCC.  A  reduction  of  at  least  10%  in  the  sum  of
he  greatest  diameters  proved  to  be  the  threshold  which
est  distinguished  responders  (n  =  256)  with  median  PFS  of
1.1  months,  from  non-responders  (n  =  78)  with  median  PFS
f  5.6  months.  During  the  ﬁrst  cycle  of  treatment,  73%  of
atients  were  detected  as  responders  according  to  the  −10%
hreshold,  while  only  19%  of  patients  had  a  response  accord-
ng  to  RECIST  criteria  (threshold  of  −30%).
The  usefulness  of  this  response  threshold  at  −10%
as  conﬁrmed  in  two  studies  on  independent  populations
24,25].  The  main  limitation  to  use  this  threshold  is  that,
T  with  all  possible  response  combinations.
SD  PD  —  —
No  PD  —  PD  —
No  —  —  Yes
SD  PD  PD  PD
rogressive disease.
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Table  3  Methods  of  evaluating  the  efﬁcacy  of  the  new  targeted  therapies  using  size  and/or  attenuation.
Criteria  Choice  of
lesions
Complete
response
Partial  response  Stable  disease  Progressive
disease
RECIST  1.1  Size  of
lesions  ≥  10  mm
on  CT
Size  of
lesions  ≥  15  mm
on  chest  X-ray
Maximum  of  5
lesions
Complete
regression  of
all lesions
Regression  in  size  of  target
lesions  ≥  30%
Neither  partial
response  nor
progressive
disease
Increase  in
size  ≥  20%
Appearance  of
a  new  lesion
Modiﬁed  RECIST  Size  of
lesions  ≥  10  mm
on  CT
Maximum  of
10 lesions
Not deﬁned  Regression  in  size  of  target
lesions  ≥  10%
Not  deﬁned  Not  deﬁned
Choi  Size  of
lesions  ≥  15  mm
Maximum  of
10 lesions
Complete
regression  of
all lesions
Regression  in  size  ≥  10%  OR
regression  in  mean
attenuation  of  target
lesions  ≥  15%
Neither  partial
response  nor
progressive
disease
Increase  in
size  of  target
lesions  ≥  10%
and  non-
responders  in
terms  of
attenuation
Appearance  of
a  new  lesion
Modiﬁed  Choi  Size  of
lesions  ≥  15  mm
Maximum  of
10 lesions
Complete
regression  of
all lesions
Regression  in  size  ≥  10%  PLUS
regression  in  mean
attenuation  of  target
lesions  ≥  15%
Neither  partial
response  nor
progressive
disease
Increase  in
size  of  target
lesions  ≥  10%
and  non-
responders  in
terms  of
attenuation
Appearance  of
a  new  lesion
SACT  Size  of
lesions  ≥  10  mm
Maximum  of
10 lesions
Regression  in  size  of  target
lesions  ≥  20%
OR  regression  in  mean
attenuation  ≥  40  HU  in  at
least  one  target  lesion
(excluding  the  lungs)
OR  regression  in  size  of  the
tumour  ≥  10%  and  regression
in  attenuation  ≥  20  HU  in  half
e  ta
ludin
Increase  in
size  ≥  20%
Appearance  of
a  new  lesion
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n  patients  with  small  lesions,  a  10%  change  in  size  may  be
ithin  the  margin  of  error  of  the  measurement.
riteria combining size measurements and CT
ttenuation
igniﬁcant  changes  in  CT  tumour  attenuation  have  been
bserved  with  targeted  therapies.  The  CT  enhancement,
r  the  attenuation  after  contrast  agent  injection,  is  related
o  the  amount  of  blood  reaching  the  tumour,  and  thus
ndirectly  to  tumour  angiogenesis  [26,27].  In  metastatic
a
t
irget  lesions
g  the  lungs)
CC,  the  highest  pretreatment  attenuation  values  have
een  associated  with  a  higher  response  rate  with  sunitinib
r  sorafenib  [28],  allowing  the  individual  response  of  each
etastatic  lesion  to  be  predicted  [25,29]. These  changes
n  lesion  attenuation  induced  by  the  treatment  are  possibly
ssociated  with  the  therapeutic  response  because  they
eﬂect  the  necrosis  induced  by  inhibition  of  the  tumour
essels  [30].  Conversely,  increase  in  attenuation  could  be
ssociated  with  disease  progression.
To  date,  three  different  response  evaluation  criteria  that
ake  into  account  changes  in  attenuation  have  been  studied
n  patients  with  mRCC:  the  Choi  criteria,  the  modiﬁed  Choi
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criteria  and  the  size  and  attenuation  in  CT  criteria  (SACT)
(Table  3).
Choi  criteria
Benjamin  et  al.  [31]  and  Choi  et  al.  [32]  developed  eval-
uation  criteria  in  order  to  detect  the  efﬁcacy  of  imatinib
in  patients  with  gastrointestinal  stromal  tumours  (GIST).
Imatinib  is  known  to  induce  considerable  tumour  necro-
sis,  which  can  be  accompanied  by  a  paradoxical  increase  in
tumour  size,  thus  simulating  progression.  The  Choi  criteria
therefore  combine  changes  in  tumour  attenuation  expressed
in  Hounsﬁeld  units  (HU)  with  size  to  determine  tumour
response.
According  to  Choi  et  al.,  a  PR  is  deﬁned  as  a  decrease
greater  or  equal  to  10%  in  a  tumour  size  measurement  or
a  reduction  greater  or  equal  to  15%  in  the  attenuation  of
target  lesions  measured  using  contrast-enhanced  CT  (Fig.  3),
while  PD  is  deﬁned  as  an  increase  in  size  greater  or  equal
to  10%  that  does  not  meet  the  PR  criteria  through  a  change
in  attenuation.  In  GIST  patients  treated  with  imatinib,  the
Choi  criteria  showed  signiﬁcantly  better  correlation  with  the
survival  rate  than  RECIST.It  was  naturally  considered  that  the  Choi  criteria  might
be  useful  for  identifying,  at  an  early  stage  of  treatment,
the  patients  with  mRCC  who  are  responding  or,  conversely,
in  whom  there  is  progression.
t
s
r
a
Figure 3. Target lesions according to Choi. Three lesions in this patient
measurable according to Choi criteria. a: liver lesion of 134 HU; b: enlarge
of the site of nephrectomy of 139 HU. The pretreatment mean of the attets  533
One  study  evaluated  the  Choi  criteria  in  55  patients  with
RCC  treated  with  sunitinib  [33]. During  treatment,  the
edian  attenuation  of  the  tumours  decreased  from  66  to
7  HU.  According  to  the  Choi  criteria,  36  patients  (65%)  had
 PR,  six  patients  (11%)  had  a  SD,  and  13  patients  (24%)  had
D  at  the  ﬁrst  evaluation  after  the  start  of  treatment.  Nine-
een  of  the  36  patients  with  a  PR  presented  it  based  only  on
he  criterion  of  a  decrease  in  attenuation  greater  or  equal
o  15%.  Patients  with  a PR  according  to  the  Choi  criteria
ad  longer  PFS  and  OS  than  those  who  were  considered  to
e  non-responders.  At  the  ﬁrst  evaluation,  the  Choi  criteria
ad  therefore  a  clearly  better  predictive  value  for  PFS  and
S  than  the  RECIST.
On  the  other  hand,  the  deﬁnition  of  progression  according
o  Choi  was  debated  in  this  study.  Indeed,  some  patients
onsidered  as  progressing  had  prolonged  PFS  (3—10  months).
onsequently,  van  der  Veldt  et  al.  concluded  that  the  Choi
riteria  do  not  change  the  clinical  management  of  patients
ith  mRCC  treated  with  sunitinib.
odiﬁed  Choi  criteria
athan  et  al.  [34]  used  modiﬁed  Choi  criteria,  according
o  which  there  needs  to  be  a  reduction  both  in  terms  of  the
ize  and  attenuation  of  target  lesions,  to  deﬁne  an  objective
esponse.  With  these  criteria,  a  PR  is  therefore  deﬁned  as
 reduction  in  tumour  size  greater  or  equal  to  10%  PLUS
 selected as target lesions according to RECIST can be considered as
d lymph node of the root of the mesentery of 122 HU; c: tissue lesion
nuation of this patient is measured as (134 + 122 + 139)/3 = 132 HU.
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 reduction  in  the  attenuation  of  target  lesions  greater  or
qual  to  15%  measured  by  contrast-enhanced  CT.
In  this  study,  32  patients  with  mRCC  and  treated  with
unitinib  or  cediranib  were  evaluated.  Ten  had  to  be
xcluded  from  the  analysis  because  no  contrast  agent  was
njected  (due  to  renal  impairment):  this  is  a  limitation  to  any
riteria  that  use  density.  In  the  end,  only  20  patients  could
e  evaluated,  with  ﬁve,  nine,  and  13  patients  showing  a  par-
ial  response  (PR)  according  respectively  to  the  RECIST,  Choi
nd  modiﬁed  Choi  criteria.  The  group  concluded  that  the
odiﬁed  Choi  criteria  provided  a  better  median  assessment
f  progression-free  survival  time,  but  this  study  is  of  limited
alue  due  to  its  statistical  weakness  with  a  population  of
nly  20  patients.
ize  and  attenuation  in  CT  (SACT)  criteria
ccording  to  the  SACT  criteria  [35],  a  positive  response  is
eﬁned  as:
a reduction  in  size  greater  or  equal  to  20%;
OR  a  reduction  in  mean  attenuation  greater  or  equal  to
40  HU  in  at  least  one  target  lesion  (excluding  the  lungs);
OR  a  reduction  in  size  of  the  tumour  greater  or  equal  to
10%  and  a  reduction  in  mean  attenuation  greater  or  equal
to  20  HU  in  half  of  the  target  lesions  (excluding  the  lungs);
Patients  are  classiﬁed  as  non-responders  when  there  is
n  increase  in  tumour  size  greater  or  equal  to  20%  or  devel-
pment  of  new  lesions.  In  all  other  cases,  they  are  stable.
In  the  SACT  criteria,  mean  attenuation  is  measured  by
aking  mean  volumetric  attenuation  measurements  (HU)  for
ach  target  lesion  using  a  3D  software  (Oncocare,  Siemens
ealthcare).  Volumetric  measurements  are  calculated  after
emi-automatic  contouring  of  the  borders  of  the  lesions
sing  multiplanar  images  (in  three  orthogonal  planes)  for  3D
estitution  of  the  target  lesions,  to  be  saved  and  examined
y  a  second  observer.
Pulmonary  lesions  cannot  be  measured  because  of  errors
ue  to  partial  volume  averaging  between  the  soft  tissues
nd  the  air.  This  is  a  potential  limitation  to  the  use  of  the
ACT  criteria  in  patients  with  mRCC,  where  the  lungs  are  a
requent  metastatic  site.
The  study  by  Dennis  Smith  et  al.  [35]  examined  53
atients  with  metastatic  clear  cell  cancer  receiving  sunitinib
r  sorafenib  as  ﬁrst-line  treatment.  The  size  and  attenu-
tion  in  CT  criteria  (SACT)  were  evaluated  and  compared
ith  the  standards  of  the  response  evaluation  criteria  for
olid  tumours  (RECIST)  and  with  the  modiﬁed  Choi  criteria,
omparing  progression-free  survival  of  responders  vs.  non-
esponders  according  to  each  criteria.  The  authors  showed
hat  the  most  useful  response  criterion  was  reduction  by
ore  than  40%  in  the  attenuation  of  at  least  one  lesion.
y  deﬁning  clinical  beneﬁt  as  absence  of  progression  for
50  days  (8—9  months),  the  test  was  able  to  detect  75%  of
esponders  and  100%  of  non-responders.  Thus,  if  none  of
he  patient’s  lesions  had  reduced  in  attenuation,  they  pro-
ressed  ‘rapidly’  (in  <  250  days).  RECIST  and  the  modiﬁed
hoi  criteria  only  detected  16%  of  responders  and  100%
f  non-responders  and  93%  of  responders  and  44%  of  non-
esponders,  respectively.
There  are  several  limitations  to  the  current  use  of  crite-
ia  based  on  attenuation  in  patients  with  mRCC  treated
ith  targeted  agents.  The  time  between  the  injection  of
b
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he  intravenous  contrast  agent  and  the  acquisition  must  be
bserved.  In  addition,  the  injection  of  contrast  agents  may
ot  be  possible  in  a  number  of  mRCC  patients,  who  are  often
ephrectomised,  since  the  administration  of  iodinated  con-
rast  agents  is  contraindicated  in  patients  with  renal  failure.
inally,  in  the  case  of  SACT,  image  analysis  software  needs
o  be  used  for  measuring  attenuations  of  a previously  con-
oured  volume,  but  is  not  universally  available  on  all  imaging
orkstations.
erfusion based criteria (dynamic imaging of
he microcirculation)
ynamic  contrast-enhanced  (DCE)  imaging  techniques
llowing  analysis  of  tumour  vascularisation  have  been  under
evelopment  for  several  years.  They  aim  at  speciﬁcally  eval-
ating  tumour  vessels  so  as  to  detect  the  direct  biological
ffect  of  anti-angiogenic  treatments,  rather  than  their  indi-
ect,  late  effects  on  the  size  of  tumours  [36].
The  principle  of  dynamic  imaging  is  monitoring  the  biodis-
ribution  of  a contrast  agent  that  acts  as  a  tracer.  After
ntravenous  injection,  the  tracer  is  carried  by  the  circu-
ation  into  the  tissues  and,  depending  on  its  size,  diffuses
hrough  the  endothelial  barrier  resulting  in  its  distribution
n  the  interstitial  space.  Imaging  follows  the  distribution  of
he  tracer  by  measuring  the  changes  in  enhancement  of  ves-
els  and  tissues  over  time  [37,38].  Acquisition  is  a  repeated
eries  of  images  centred  on  a  speciﬁc  lesion,  in  order  to
ollow  modiﬁcations  over  time  in  the  concentration  of  the
ontrast  agent  in  the  tissue.  The  contrast  agent  is  injected
ntravenously  during  acquisition.  The  data  are  then  trans-
itted  to  a  workstation  so  that  regions  of  interest  (ROI)  can
e  deﬁned  in  order  to  obtain  signal  variation  curves  over
ime.  Image  analysis  software  apply  mathematical  models
ielding  more  or  less  complex  microvascular  parameters,  or
urely  descriptive  parameters  (such  as  the  area  under  the
urve  and  percentage  enhancement).  This  technique  can  be
sed  with  CT,  MRI  or  ultrasound  (Fig.  4).
Some  teams  have  shown  the  advantages  of  perfusion
maging  for  assessing  the  response  to  anti-angiogenics  in
etastatic  renal  cancer,  using  CT,  MRI  or  ultrasound.
Fournier  et  al.  [14]  studied  the  usefulness  of  perfusion
arameters  using  CT  in  two  phase  III  trials  involving  51
atients  with  mRCC  receiving  anti-angiogenic  treatments
sunitinib  or  sorafenib)  vs.  placebo  or  interferon  alpha.
he  results  showed  higher  baseline  perfusion  parameters
n  responders  than  in  stable  patients  but  this  was  not
igniﬁcantly  predictive  of  survival.  Secondly,  there  was
 signiﬁcant  reduction  in  tissue  blood  ﬂow  (162.5  vs.
6.7  ml/min/100  ml,  P  =  0.0002)  and  tissue  blood  volume
9.1  vs.  3.9  ml/100  ml,  P  <  0.0001)  in  patients  receiving  anti-
ngiogenic  treatment  as  early  as  the  ﬁrst  cycle  of  treatment.
he  study  concluded  that  perfusion  parameters  could  help
redict  the  biological  response  to  anti-angiogenic  agents
efore  the  start  of  treatment  and  help  detect  an  effect  after
nly  one  cycle  of  treatment  [14].
A  disadvantage  of  perfusion  CT  is  the  radiation  dose,
ecause  series  of  scans  are  repeated.  Studies  have  there-
ore  been  conducted  using  MRI  (with  injection  of  contrast
gent  or  spin  labelling  [ASL])  [39—44].  However,  analysis  of
CE-MRI  data  is  complex,  and  the  conversion  from  signal
Radiological  evaluation  of  response  to  anti-angiogenic  treatments  535
Figure 4. DCE-CT. a: ROI are placed on a vessel (here, the descending aorta) and on the tumour (here, an anterior mediastinal mass).
These ROI are automatically carried over onto all the images of the DCE series; b: from the regions drawn on the image, enhancement time
curves are obtained (in red for the aorta, black for the tumour), corresponding to the change in the signal during injection of a bolus of
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colour coding, generating a parametric map image, here, a map of 
intensity  to  concentration  makes  absolute  quantiﬁcation
more  difﬁcult  than  with  CT.  In  addition,  since  quantiﬁcation
is  dependent  on  the  acquisition  parameters,  it  is  difﬁcult  to
obtain  results  that  are  reproducible  between  centres.  Less
restrictive  parameters  such  as  Ktrans  have  been  used  to
quantify  vascularisation  in  MRI  [39—41].  The  Ktrans  transfer
constant  simultaneously  reﬂects  the  blood  ﬂow  (perfusion)
and  its  passage  into  the  extracellular  space  through  the
vascular  endothelium  (permeability).  Ktrans  is  thus  a  param-
eter  that  depends  on  capillary  ﬂow,  the  endothelial  surface
area  and  capillary  permeability.  It  is  simpler  to  calculate  and
does  not  require  hypotheses  to  be  presented  to  distinguish
between  perfusion  and  permeability.  It  is  a  good  biomarker
for  the  activity  of  any  treatment,  but  precautions  must  be
taken  when  using  it,  particularly  to  always  ensure  the  same
acquisition  conditions  [39].  In  conditions  where  exchanges
are  limited  by  blood  ﬂow  (perfusion  >  permeability),
Ktrans  approximates  to  permeability;  in  conditions
where  exchanges  are  limited  by  permeability  (permeabil-
ity  >  perfusion),  Ktrans  approximates  to  blood  ﬂow  [45,46].
In  a  phase  II  study  in  17  patients  with  mRCC  receiving
sorafenib,  a  60%  reduction  in  Ktrans  was  shown  [42].  The
percentage  reduction  in  Ktrans  and  the  change  in  tumour
size  in  CT  scans  were  signiﬁcantly  correlated  with  PFS.  In
addition,  tumours  with  a  high  Ktrans  before  treatment  were
also  signiﬁcantly  associated  with  better  progression-free
survival.
Ultrasound  can  also  be  used  for  monitoring  anti-
angiogenic  treatments  [16,47].  A  number  of  clinical  trials
i
r
r
[racted mathematically and plotted on each pixel of the image by
e blood volume.
ith  targeted  agents  have  included  DCE-US  and  have  shown
hat  the  parameters  obtained  can  be  correlated  with  tumour
esponse  [16,48].  DCE-US  was  studied  in  patients  with  mRCC
eing  treated  with  sunitinib  [49]  or  sorafenib  [16,48].  In  38
atients  treated  with  sunitinib  for  mRCC,  signiﬁcantly  dif-
erent  values  were  found  between  parameters  at  baseline
nd  15  days  after  the  start  of  treatment,  which  correlated
ith  PFS  [49].  An  increase  in  time  to  peak  intensity  greater
han  29%  and  a  decrease  in  the  washout  slope  greater  than
6%  were  associated  with  increased  PFS  and  OS  [49]. This
echnique  is  of  interest  due  to  its  ease  of  use,  and  the  pos-
ibility  of  repeating  measurements  without  adverse  effects.
ositron emission tomography (PET)
valuation  of  [18F]  FDG  PET/CT
ET  using  [18F]  ﬂuoro-2-deoxy-D-glucose  ([18F]  FDG)  is  the
unctional  imaging  tool  most  commonly  used  in  oncology
50,51].  The  use  of  [18F]  FDG  is  based  on  the  fact  that  malig-
ant  tumour  cells  have  a  high  rate  of  glucose  metabolism,
nd  are  therefore  just  as  avid  for  its  analogue,  [18F]  FDG,
hich  cannot  be  metabolised  and  thus  remains  trapped  in
he  cells.
However,  the  use  of  [18F]  FDG  PET  in  patients  with  mRCC
s  limited,  because  RCCs  and  their  metastases  have  a  low
ate  of  glucose  metabolism  [51—55].  A  negative  [18F]  FDG
esult  does  not  exclude  the  presence  of  RCC.  The  use  of
18F]  FDG  PET  is  only  accepted  as  an  addition  to  conﬁrm
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quivocal  progression  in  the  rare  cases  where  the  tumour
ccumulates  FDG,  as  has  been  proposed  in  RECIST  version
.1.
Other  tracers  for  PET  have  been  developed,  such  as  [11C]
cetate,  which  accumulates  in  tumour  cells  due  to  very
ctive  membrane  lipid  metabolism  [56,57].  [11C]  acetate
s  incorporated  into  the  tricarboxylic  acid  cycle  by  acetyl
oenzyme  A,  and  then  into  cell  membrane  phospholipids.  A
ecent  study  showed  a  reduction  in  the  absorption  of  [11C]
cetate  after  only  2  weeks  of  treatment  with  sunitinib  [58].
valuation  of  [18F]-FMISO  PET/CT
ypoxia  of  malignant  tumours  can  affect  the  results  of  anti-
ancer  treatments  because  it  can  produce  resistance  to
hemotherapy  and  radiotherapy.  [18F]-ﬂuoromisonidazole
[18F]-FMISO)  is  the  agent  most  frequently  used  to  assess
umour  hypoxia  in  vivo  with  PET.  It  is  a  nitroimidazole  deriva-
ive  and,  like  all  the  molecules  in  this  group,  is  selectively
rapped  in  hypoxic  cells.  This  tracer  freely  penetrates  into
ormal  and  hypoxic  cells  by  diffusion,  and  within  the  cells,  it
an  be  reduced  by  a  number  of  enzymes.  In  normoxic  cells,
itroreduction  is  not  O2-dependent  and  is  rapidly  reversible.
n  hypoxic  cells,  this  reduction  leads  to  the  formation  of
ydroxylamine  followed  by  fragmentation  of  the  tracer,  pro-
ucing  chains  which  bind  to  the  intracellular  proteins.  This
inding  is  closely  dependent  on  the  oxygen  concentration
59].  Labelled  with  18F,  FMISO  allows  tumour  hypoxia  to  be
maged  by  PET.
It  has  been  shown  in  vitro  that  (1)  the  rate  of  [18F]-FMISO
inding  in  hypoxic  cells  could  be  28  times  higher  than  in
ormoxic  cells,  (2)  [18F]-FMISO  did  not  accumulate  when
he  O2 pressure  in  the  interstitial  tissue  was  greater  than
0  mm  Hg  [60].
[18F]-FMISO  is  currently  only  available  in  France  for  pre-
linical  applications.
Hugonnet  et  al.  [18]  evaluated  initial  tumour  hypoxia
n  mRCC  and  the  changes  after  treatment  with  sunitinib
sing  PET  imaging  with  [18F]-FMISO.  They  demonstrated
hat  sunitinib  at  ﬁrst  reduced  tumour  hypoxia  probably
y  normalising  the  tumour’s  vascular  supply.  However,  this
tudy  did  not  produce  statistically  signiﬁcant  results  demon-
trating  that  tumour  hypoxia,  initially  or  after  1  month  of
reatment,  could  be  linked  to  a  greater  risk  of  progression
r  death  in  patients  treated  with  sunitinib  for  mRCC.
ther functional MRI techniques:
iffusion-weighted  MRI (DW-MRI) and blood
xygenation level-dependent MRI (BOLD MRI)
iffusion-weighted  MRI
he  principle  of  diffusion-weighted  MRI  is  exploration  of  the
icroscopic  movement  of  water.  Two  intense,  symmetrical
radients  are  applied,  causing  dephasing  then  rephasing  of
pins  in  the  voxel  [61].  Moving  water  molecules  will  leave  the
oxel  and  be  incompletely  rephased,  resulting  in  a  signal  loss
62].  According  to  the  Intra  Voxel  Incoherent  Motion  concept
IVIM),  initially  set  out  by  Denis  Le  Bihan,  molecules  can
ove  in  two  ways:  Brownian  diffusion  resulting  from  random
hermal  molecular  movements,  and  movement  within  the
apillary  network  of  microvessels  due  to  the  pseudo-random
i
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rientation  of  capillaries  at  the  voxel  scale,  reﬂecting  per-
usion  [63].
Diffusion  is  characterised  by  the  b  factor,  reﬂecting  the
trength  of  the  gradient.  The  higher  b  factor  is,  the  more  the
equence  is  diffusion-weighted.  The  b  factor  depends  on  the
haracteristics  of  the  diffusion  gradients  (amplitude,  length
f  time  applied,  time  between  the  two  gradients,  distance
part)  [64].  To  correctly  determine  the  signal  loss  respec-
ively  due  to  Brownian  diffusion  and  perfusion,  several  b
alues  must  be  applied  and  the  signal  subjected  to  mathe-
atical  analysis  to  separate  the  two  components  (diffusion
nd  perfusion).
When  using  low  b  values,  signal  loss  is  mainly  due  to  per-
usion  [63].  It  could  then  be  possible  to  estimate  tumour
erfusion  without  injecting  a contrast  agent,  and  conse-
uently  assess  the  effect  of  anti-angiogenic  treatments  on
umour  vascularisation.
When  using  high  b values,  signal  loss  is  mainly  due
o  Brownian  diffusion.  Intracellular  water  molecules  have
uch  more  limited  movement  than  water  molecules  in  the
xtracellular  space,  particularly  because  of  the  existence
f  cell  membranes  and  the  cytoskeleton.  A  very  cellular  tis-
ue,  such  as  tumour  tissue,  will  thus  have  a  low  diffusion
oefﬁcient  (the  molecules  diffusing  little)  [65].
In  RCC,  DW-MRI  has  been  evaluated  mainly  for  character-
sing  primary  tumours  [66,67].  Experience  with  DW-MRI  for
onitoring  mRCCs  during  treatment  is  limited  [68]. The  only
tudy  that  evaluated  diffusion-weighted  MRI  in  monitoring
etastatic  renal  cancer  during  anti-angiogenic  treatment
s  the  study  by  Desar  et  al.  [69]  on  a  series  of  10  patients
eceiving  sunitinib.  Diffusion-weighted  MRI  was  performed
efore,  and  at  D3  and  D10  after  beginning  treatment.  The
iffusion-weighted  sequence  was  performed  with  three  b
alues  (50,  300,  and  600  s/mm2),  but  generating  a  single
DC  value.  In  this  study,  the  ADC  had  increased  signiﬁ-
antly  by  the  third  day,  which  was  thought  to  be  linked
o  the  development  of  necrosis  and  cellular  oedema,  fol-
owed  by  a  decrease  by  the  10th  day  that  could  be  explained
y  the  decrease  in  blood  ﬂow  due  to  dehydration  and  cell
eath.
Few  data  are  available  concerning  the  effect  of  anti-
ngiogenic  treatments  on  perfusion  or  diffusion  in  the
umours  [70].  In  addition,  there  is  no  consensus  in  the  liter-
ture  concerning  the  choice  of  b  values  [71].
OLD  MRI
lood  Oxygenation  Level-Dependent  MRI  (BOLD  MRI),  also
alled  intrinsic  susceptibility  imaging,  is  a  technique  which
s  sensitive  to  tissue  oxygenation.  Haemoglobin  in  its
eoxygenated  form  has  paramagnetic  properties,  i.e.  it
odiﬁes  the  local  magnetic  ﬁeld  in  a  tissue.  In  practice,
his  means  that  there  is  a  signal  loss  proportional  to  the
mount  of  deoxyhaemoglobin  in  the  red  blood  cells  of  the
essels  of  a  tissue,  provided  that  a suitable  sequence  is
erformed  known  as  a  gradient  echo  sequence.  However,
t  follows  that  the  signal  loss  is  also  inﬂuenced  by  other
actors  such  as  the  amount  of  red  blood  cells  in  the  tissue,
tself  related  to  the  number  of  vessels  (the  blood  volume),
nd  the  velocity  of  blood  circulation  (blood  ﬂow)  [72].  This
maging  thus  reﬂects  the  overall  state  of  oxygenation  of
 tissue,  combining  all  of  these  parameters.  It  therefore
men
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seems  logical  to  take  an  interest  in  this  technique  for  eval-
uating  anti-angiogenic  treatments.  In  preclinical  studies
in  animals  [73],  it  has  been  shown  that  the  R2*  value  of
tumours  decreases  dose-dependently  with  anti-vascular
treatment  in  prolactinoma  and  ﬁbrosarcoma  models.  There
have  not  yet  been  any  studies  analysing  the  usefulness  of
BOLD  MRI  in  the  response  to  anti-angiogenic  treatment  in
humans.
Conclusion
There  are  many  techniques  available  in  clinical  practice
for  evaluating  response  to  treatment,  providing  an  alter-
native  to  purely  morphological  imaging.  However,  studies  in
humans  are  still  at  the  preliminary  stage,  and  the  medical
community  needs  to  start  to  consider  how  to  evaluate  their
usefulness  in  daily  practice.
The  use  of  CT  has  the  advantage  of  being  the  tech-
nique  used  in  regular  follow-up  for  monitoring  patients.
Size  criteria  are  the  easiest  to  use  in  practice,  possibly
by  modifying  the  threshold  from  which  point  the  patient
is  considered  to  be  a  responder.  This  is  what  oncolo-
gists  do  in  practice,  since  they  are  satisﬁed  that  absence
of  progression  shows  that  their  treatment  is  effective.
As  far  as  the  usefulness  of  attenuation  measurements
is  concerned,  this  could  be  improved  by  functional  per-
fusion  acquisitions,  providing  additional  information  on
the  physiological  effect  of  anti-angiogenic  agents.  This
technique  might  be  useful  where  dose  adjustment  is  nec-
essary,  when  side  effects  are  poorly  tolerated.  Indeed,  it
would  allow  testing  the  continuing  effect  of  the  treat-
ment  on  tumour  vascularisation,  despite  the  reduction  in
dose.
MRI  allows  a  ‘one  stop  shop’  strategy  to  be  used  in  a  single
examination  which  could  include  morphological,  dynamic,
diffusion  and  BOLD  techniques.  MRI  is  limited  by  its  higher
cost  and  lower  availability.  In  addition,  the  acquisition  tech-
nique  greatly  inﬂuences  signal,  and  it  is  more  difﬁcult  to
compare  between  one  machine  and  another  and  from  one
protocol  to  another.  It  remains  a  cognitive  tool  essential
for  understanding  the  phenomena  underlying  the  action  of
anti-angiogenic  agents.
Ultrasound  does  not  allow  whole  body  evaluation  of  a
metastatic  disease.  However,  as  far  as  the  quantiﬁcation  of
vascularisation  by  dynamic  imaging  is  concerned,  its  advan-
tages  are  its  safety,  its  low  cost  and  its  ease  of  access.
It  is  not  therefore  possible  to  propose  a  unanimously
acknowledged  criterion  for  evaluating  tumour  response  to
targeted  therapies.  Systematic  validation  of  this  criterion
would  be  necessary  for  it  to  provide  a  basis  for  therapeu-
tic  decisions,  by  evaluating  reproducibility,  repeatability,
and  inter-individual  and  inter-machine  variability.  It  would
then  have  to  be  validated  on  large  independent  multi-
centre  populations,  and  ultimately,  the  beneﬁt  of  use  of
this  criterion  for  the  patient’s  survival  or  quality  of  life
would  have  to  be  demonstrated.  Such  studies  are  very
costly  and  complex  to  implement.  However,  oncologists  are
expressing  a  real  need  for  this  for  guiding  their  choice  of
therapy,  as  is  the  pharmaceutical  industry,  and  radiologists
must  take  an  active  part  in  developing  and  validating  new
tools.
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